Trial Profile
Phase IIa Trial With PD-L1 IO103 Vaccination With Montanide in Patients With Basal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs IO-103 (Primary) ; Montanide ISA-51
- Indications Basal cell cancer; Carcinoma
- Focus Therapeutic Use
- 02 Oct 2020 Status changed from recruiting to completed.
- 31 May 2020 Results assessing efficacy and safety of IO103, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 22 Nov 2018 Status changed from not yet recruiting to recruiting.